Emile Yu is a M.S. candidate studying Biostatistics at the Harvard T.H. Chan School of Public Health. She has a B.A. & B.Sc. in Economics and Biomedical Sciences from McGill University in Montreal, Canada. She is currently working at the Dana-Farber Cancer Institute doing research on the effect of gemcitabine singlet chemotherapy versus doublet chemotherapy on overall survival and progression-free survival in metastatic pancreatic cancer patients.